Myriad Genetics (English Wikipedia)

"ACLU Challenges Patents on Breast Cancer Genes". American Civil Liberties Union. 6 June 2008.
"Association for Molecular Pathology v. Myriad Genetics". ACLU. Retrieved 17 May 2013. On May 12, 2009, the ACLU and the Public Patent Foundation (PUBPAT) filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer, BRCA1 and BRCA2, are unconstitutional and invalid. On November 30, 2012, the Supreme Court agreed to hear argument on the patentability of human genes. The ACLU argued the case before the U.S. Supreme Court on April 15, 2013. We expect a decision this summer.

benzinga.com

Gross, Charles (7 October 2015). "Myriad Genetics, Tufts Health Plan Sign 3-Year Contract to Cover Prolaris for Members With Localized Prostate Cancer". Benzinga. Retrieved 16 November 2021.

businessweek.com

"Myriad Genetics slips on Supreme Court review". Bloomberg Business Week. 3 December 2012. Archived from the original on 7 December 2012.

cancernetwork.com

"Myriad Genetics' RiskScore Accurately Identifies Breast Cancer Risk in Undiagnosed Women of All Ancestries". Cancer Network. 3 August 2021. Retrieved 16 November 2021.

clinicalomics.com

"Clinical Urologists Group Supports Genomic Testing for Prostate Cancer". ClinicalOMICs. 6 March 2018. Retrieved 9 March 2018.

doi.org

Hall, J.; Lee, M.; Newman, B.; Morrow, J.; Anderson, L.; Huey, B.; King, M. (1990). "Linkage of early-onset familial breast cancer to chromosome 17q21". Science. 250 (4988): 1684–1689. Bibcode:1990Sci...250.1684H. doi:10.1126/science.2270482. PMID 2270482.
Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P. A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L. M.; Ding, W.; Et, A. (1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". Science. 266 (5182): 66–71. Bibcode:1994Sci...266...66M. doi:10.1126/science.7545954. PMID 7545954.
Cook-Deegan, Robert; Derienzo, Christopher; Carbone, Julia; Chandrasekharan, Subhashini; Heaney, Christopher; Conover, Christopher (1 March 2010). "Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers". Genetics in Medicine. 12 (4): S15–18, S20–24, S27–28. doi:10.1097/GIM.0b013e3181d5a67b. PMC 3047448. PMID 20393305.
Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.; Ding, W.; Et, al. (7 October 1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". Science. 266 (5182): 66–71. Bibcode:1994Sci...266...66M. doi:10.1126/science.7545954. PMID 7545954.

genengnews.com

"Myriad to Acquire Assurex Health for up to $410M". 4 August 2016.

genomeweb.com

"Myriad Genetics Completes Acquisition of Counsyl". GenomeWeb. Retrieved 19 October 2018.

harvard.edu

ui.adsabs.harvard.edu

Hall, J.; Lee, M.; Newman, B.; Morrow, J.; Anderson, L.; Huey, B.; King, M. (1990). "Linkage of early-onset familial breast cancer to chromosome 17q21". Science. 250 (4988): 1684–1689. Bibcode:1990Sci...250.1684H. doi:10.1126/science.2270482. PMID 2270482.
Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P. A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L. M.; Ding, W.; Et, A. (1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". Science. 266 (5182): 66–71. Bibcode:1994Sci...266...66M. doi:10.1126/science.7545954. PMID 7545954.
Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.; Ding, W.; Et, al. (7 October 1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". Science. 266 (5182): 66–71. Bibcode:1994Sci...266...66M. doi:10.1126/science.7545954. PMID 7545954.

jurist.org

"Paper Chase: ACLU asks Supreme Court to rule on gene patent case". JURIST. 8 December 2011. Retrieved 6 March 2014.

justia.com

news.justia.com

"Association For Molecular Pathology et al v. United States Patent and Trademark Office et al". Justia.com. 12 May 2009.

loc.gov

webarchive.loc.gov

"ACLU v. Myriad Genetics opinion" (PDF). 29 March 2010. Archived from the original (PDF) on 7 April 2010. Retrieved 30 March 2010.

myriad.com

"Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives". 24 February 2021.
"Myriad Genetics and Subsidiary Locations and Directions". Myriad Genetics, Inc. Retrieved 16 November 2021.

investor.myriad.com

"Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Metastatic Breast Cancer | Myriad Genetics, Inc". investor.myriad.com. Retrieved 16 November 2021.
"Myriad Applauds the Court of Appeals' Decision to Uphold Gene Patenting". Myriad Genetics. 29 July 2011. Retrieved 20 November 2011.

newsweek.com

blog.newsweek.com

Begley, Sharon (29 March 2010). "In Surprise Ruling, Court Declares Two Gene Patents Invalid". Newsweek. Archived from the original on 19 April 2010. Retrieved 29 March 2010.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hall, J.; Lee, M.; Newman, B.; Morrow, J.; Anderson, L.; Huey, B.; King, M. (1990). "Linkage of early-onset familial breast cancer to chromosome 17q21". Science. 250 (4988): 1684–1689. Bibcode:1990Sci...250.1684H. doi:10.1126/science.2270482. PMID 2270482.
Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P. A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L. M.; Ding, W.; Et, A. (1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". Science. 266 (5182): 66–71. Bibcode:1994Sci...266...66M. doi:10.1126/science.7545954. PMID 7545954.
Health Quality Ontario (2017). "Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test". Ontario Health Technology Assessment Series. 17 (4): 1–39. ISSN 1915-7398. PMC 5433545. PMID 28515818.
Cook-Deegan, Robert; Derienzo, Christopher; Carbone, Julia; Chandrasekharan, Subhashini; Heaney, Christopher; Conover, Christopher (1 March 2010). "Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers". Genetics in Medicine. 12 (4): S15–18, S20–24, S27–28. doi:10.1097/GIM.0b013e3181d5a67b. PMC 3047448. PMID 20393305.
Easton DF, Bishop DT, Ford D, Crockford GP (24 January 2014). "Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium". Am. J. Hum. Genet. 52 (4): 678–701. PMC 1682082. PMID 8460634.
Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.; Ding, W.; Et, al. (7 October 1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1". Science. 266 (5182): 66–71. Bibcode:1994Sci...266...66M. doi:10.1126/science.7545954. PMID 7545954.

ncbi.nlm.nih.gov

Health Quality Ontario (2017). "Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test". Ontario Health Technology Assessment Series. 17 (4): 1–39. ISSN 1915-7398. PMC 5433545. PMID 28515818.
Cook-Deegan, Robert; Derienzo, Christopher; Carbone, Julia; Chandrasekharan, Subhashini; Heaney, Christopher; Conover, Christopher (1 March 2010). "Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: Comparing breast and ovarian cancers with colon cancers". Genetics in Medicine. 12 (4): S15–18, S20–24, S27–28. doi:10.1097/GIM.0b013e3181d5a67b. PMC 3047448. PMID 20393305.
Easton DF, Bishop DT, Ford D, Crockford GP (24 January 2014). "Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium". Am. J. Hum. Genet. 52 (4): 678–701. PMC 1682082. PMID 8460634.

nytimes.com

Schwartz, John; Pollack, Andrew (29 March 2010). "Judge Invalidates Human Gene Patent". The New York Times. Retrieved 29 March 2010.
Jolie, Angelina (14 May 2013). "Opinion | My Medical Choice". The New York Times. ISSN 0362-4331. Retrieved 16 November 2021.
Tamar Lewin (21 May 1996). "Move to Patent Cancer Gene Is Called Obstacle to Research". The New York Times. Retrieved 6 March 2014.
Pollack, Andrew (1 November 2010). "Gene Patent Ruling Raises Questions for Industry". The New York Times. Retrieved 6 March 2014.
Pollack, Andrew (26 March 2012). "Supreme Court Orders New Look at Gene Patents". The New York Times.
"Court Reaffirms Right of Myriad Genetics to Patent Genes". The New York Times. 16 August 2012.
Liptak, Adam (13 June 2013). "Supreme Court Rules Human Genes May Not Be Patented". The New York Times. Retrieved 13 June 2013.

owler.com

"Myriad's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile".

patentlyo.com

"ACLU v. Myriad Genetics opinion" (PDF). 29 March 2010. Archived from the original (PDF) on 7 April 2010. Retrieved 30 March 2010.

smh.com.au

Harrison, Dan (16 June 2015). "Genetic patents: Grandmother Yvonne D'Arcy takes on global giant Myriad Genetics". Sydney Morning Herald. Retrieved 14 October 2015.
Corderoy, Amy (7 October 2015). "Landmark High Court ruling on BRCA1 gene patent as pensioner wins legal case". Sydney Morning Herald. Retrieved 14 October 2015.

web.archive.org

Begley, Sharon (29 March 2010). "In Surprise Ruling, Court Declares Two Gene Patents Invalid". Newsweek. Archived from the original on 19 April 2010. Retrieved 29 March 2010.
"Myriad Genetics slips on Supreme Court review". Bloomberg Business Week. 3 December 2012. Archived from the original on 7 December 2012.

worldcat.org

search.worldcat.org

Cook-Deegan, Robert M. (1994). The gene wars : science, politics, and the human genome. New York: W.W. Norton & Co. ISBN 0-393-03572-7. OCLC 28021657.
Davies, Kevin (1995). Breakthrough : the quest to isolate the gene for hereditary breast cancer. Michael White. London: Macmillan. pp. 199–200. ISBN 0-333-61102-0. OCLC 36138590.
Jolie, Angelina (14 May 2013). "Opinion | My Medical Choice". The New York Times. ISSN 0362-4331. Retrieved 16 November 2021.
Health Quality Ontario (2017). "Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test". Ontario Health Technology Assessment Series. 17 (4): 1–39. ISSN 1915-7398. PMC 5433545. PMID 28515818.

worldcat.org

Cook-Deegan, Robert M. (1994). The gene wars : science, politics, and the human genome. New York: W.W. Norton & Co. ISBN 0-393-03572-7. OCLC 28021657.
Davies, Kevin (1995). Breakthrough : the quest to isolate the gene for hereditary breast cancer. Michael White. London: Macmillan. pp. 199–200. ISBN 0-333-61102-0. OCLC 36138590.

wsj.com

Kendall, Brent; Bravin, Jess (13 June 2013). "Supreme Court Says Human Genes Aren't Patentable". Wall Street Journal. Retrieved 13 June 2013.

xifin.com

"Xfin Health Information. Featured Customer: Myriad". XIFIN. 23 February 2017. Retrieved 16 November 2021.